Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein

Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump

(2013) J. Marcoux et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models

(2012) Amit K. Tiwari et al.   CANCER LETTERS

Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective

(2012) Andreia Palmeira et al.   CURRENT PHARMACEUTICAL DESIGN

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

(2012) Suneet Shukla et al.   DRUG RESISTANCE UPDATES

Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance

(2011) Z. Shi et al.   CANCER RESEARCH

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

(2011) Anna Brózik et al.   Expert Opinion on Drug Metabolism & Toxicology

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

(2009) S. G. Aller et al.   SCIENCE